



Friday Five

August 24, 2018

In this issue...

1. [Update on the Administration of Injections Training Program for Manitoba Pharmacists](#)
2. [Duty to Report](#)
3. [Call for Members: QA Committee](#)
4. [Recall/Shortage Update \(Valsartan/EpiPen®\)](#)
5. [Upcoming Professional Development Opportunities](#)

[Update on the Administration of Injections Training Program for Manitoba Pharmacists](#)

The Administration of Injections Training Program for Manitoba Pharmacists has been revised and updated by the College of Pharmacists of Manitoba (College) and the College of Pharmacy, University of Manitoba. Due to a change in the availability of online modules of the previous program, pharmacists wanting to complete the training program will now need to complete the "Immunization and Injection Administration Training Program – Independent Study", including the "Manitoba Module: Administration of Injections", provided by Dalhousie University. (Please see invitation link below for more information)

The next Administration of Injections Practical Skills Workshops will be held on Oct. 20th, 2018 and Oct. 27, 2018. The workshops are provided by the College of Pharmacy, University of Manitoba. For more information on registration, please see the invitation [here](#). Please note that spots for pharmacists are limited.

Professional Development Opportunities

27th Annual Provincial Palliative Care Conference

[September 13 & 14, 2018](#)

Opioid Replacement Therapy 101 Introduction to Clinical Practice

[September 13 & 14, 2018](#)
[November 22 & 23, 2018](#)

2018 Provincial Cancer Care Conference

[September 20 & 21, 2018](#)

CAPhO Oncology Fundamentals Day 2018

[September 22, 2018](#)

Health Sciences Centre Winnipeg Presents:

[The 22nd Annual Bug Day](#)

October 16, 2018

Administration of Injections Practical Skills Workshop

[October 20, 2018](#)
[October 27, 2018](#)

Duty to Report

Please be reminded of a pharmacist's duty to report, as outlined in Section 97(1) of *The Pharmaceutical Act* and Statement VIII of the Code of Ethics.

Pharmacists are required to notify the Registrar or Deputy Registrar if they believe another pharmacist is suffering from a physical or mental condition or disorder of a nature or to an extent that the pharmacist is unfit to practice and presents a risk to patient safety.

As per Section 97(2) of *The Pharmaceutical Act*, pharmacists who disclose information to the College are exempt from liability, unless the disclosure was made maliciously.

The College has received an increasing number of inquiries related to concerns of a colleague's conduct, but members have been unwilling to disclose the name of the pharmacist or practice site involved. Although the College is willing to provide guidance in such a situation, regulatory action cannot be taken without complete disclosure of the situation.

Call for Members: QA Committee

The College is actively looking for new members to join the Quality Assurance (QA) Committee.

The QA Committee's mandate is "to serve as a resource to Council by providing oversight, monitoring and evaluation of the College's Quality Assurance/Continuous Quality Improvement Program and make recommendations to Council on program enhancements for the purpose of improving pharmacy practice and patient safety."

The next meeting is scheduled for September 11, 2018, at 6:30 p.m. Teleconference is available for those who do not live in Winnipeg.

To express your interest, please email [Gus Gottfred](#) or [Ronda Eros](#).

Online Programs:

[Oral-Systemic Health Education for Non-Dental Healthcare Providers](#)

[Ordering Lab Tests for Manitoba Pharmacists](#)

Visit www.cphm.ca for more information on [Expanded Scope of Practice](#) training.

[Self-Limiting Conditions Independent Study Program](#)

Visit www.cphm.ca for more information on [Expanded Scope of Practice](#) training.

All PD opportunities are listed on the College website under

[Upcoming Professional Development Opportunities](#)

Recall/Shortage Update (Valsartan/EpiPen®)

Update on EpiPen® Shortage:

On July 30, 2018, Health Canada issued an alert regarding an anticipated shortage of EpiPen® auto-injectors during the month of August. The College has been monitoring this situation in Manitoba and nationally, and has been working in collaboration with other provincial regulatory bodies and Manitoba Health to develop guidance for pharmacists in Manitoba.

Health Canada approved epinephrine auto-injectors are still the preferred product for patients. Pharmacy professionals are encouraged to contact other pharmacies in their area to determine if an EpiPen® is available at another pharmacy in their region for a patient. In the event that an EpiPen® is not available, an epinephrine ampoule kit is an alternative option, with a prescription from a prescriber, and with patient counselling and teaching from a pharmacist.

Pre-filled epinephrine syringes or other compounding methods are not considered appropriate alternative options, due to short beyond-use dating.

The College recommends the following items to be included in an epinephrine ampoule kit³:

- 2 – 1 cc syringes and 2 needles
- Needle gauge and length:
- Infants < 18 months, 25 – 27 G, 5/8 – 1¼ inch
- Children > 18 months up to 18 years, 23 – 25 G, 5/8 to 1¼ inch
- Adult 23 – 25 G, 1 to 1¼ inch
- 2 extra needles
- 2 ampoules of epinephrine 1:1,000
- alcohol swabs, cotton balls, gauze pads
- Small sharps container (Optional)
- Case to hold syringes (e.g., pencil case, eyeglass case)
- Directions on filling syringe, where and how to administer injection, safe disposal of ampoules, needles, syringes, etc.

As communicated in the most recent College newsletter, filter needles are not required because this kit is dispensed for emergency use.

Update on Valsartan Recall:

On August 18, 2018, Health Canada expanded the recall advisory for several additional products containing the drug valsartan as a precautionary measure. The manufacturer, Zhejiang Huahai Pharmaceuticals in China, has detected an impurity, N-nitrosodimethylamine (NDMA) which is a potential human carcinogen. Valsartan products from five drug companies are affected.

To continue to support healthcare teams in managing this recall, Council passed the following motion on August 20, 2018:

That a temporary exemption to Section 2.4 of the Prescribing Practice Direction be granted, to permit Extended Practice Pharmacists working in the Primary Care setting to prescribe an appropriate alternative to valsartan for patients they have not seen and assessed in-person. Extended Practice Pharmacists are required to comply with all other prescribing requirements outlined in the legislation and Prescribing Practice Direction. This temporary exemption will expire on December 31, 2018.

College of Pharmacists of Manitoba

200 Taché Avenue, Winnipeg, MB R2H 1A7

Phone: 204.233.1411

www.cphm.ca

The **Friday Five** e-bulletin is published by the **College of Pharmacists of Manitoba** and is forwarded to every licenced pharmacist and pharmacy owner in the Province of Manitoba. Decisions of the College of Pharmacists of Manitoba regarding all matters such as regulations, drug-related incidents, etc., are published in the *Friday Five*. The College of Pharmacists of Manitoba therefore assumes that all pharmacists and pharmacy owners are aware of these matters.

To download a PDF of this e-newsletter, please click [Friday Five & Newsletter](#), on www.cphm.ca.